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Classic cardio-metabolic risk factors such as
hypertension, stroke, diabetes, and hypercholester-
olemia all increase the risk of Alzheimer’s disease.
We found increased transcription of b-secretase/
BACE1, the rate-limiting enzyme for Ab generation,
in eNOS-deficient mouse brains and after feeding
mice a high-fat, high-cholesterol diet. Up- or down-
regulation of PGC-1a reciprocally regulated BACE1
in vitro and in vivo. Modest fasting in mice reduced
BACE1 transcription in the brains, which was
accompanied by elevated PGC-1 expression and
activity. Moreover, the suppressive effect of PGC-1
was dependent on activated PPARg, likely via
SIRT1-mediated deacetylation in a ligand-indepen-
dent manner. The BACE1 promoter contains multi-
ple PPAR-RXR sites, and direct interactions among
SIRT1-PPARg-PGC-1 at these sites were enhanced
with fasting. The interference on the BACE1 gene
identified here represents a unique noncanonical
mechanism of PPARg-PGC-1 in transcriptional
repression in neurons in response to metabolic sig-
nals that may involve recruitment of corepressor
NCoR.
INTRODUCTION
Alzheimer’s disease (AD) is one of the most devastating neuro-
degenerative disorders and is characterized by the two patho-
logical hallmarks of amyloid plaques and neurofibrillary tangles.
Amyloid peptides (Ab), the major constituent of plaques, are
generated by sequential proteolytic cleavage of the amyloid
precursor protein (APP) via b-secretase (BACE1) and the g-sec-
retase complex (Hardy and Selkoe 2002). The expression and
activity levels of BACE1 are elevated in AD brains and correlate
with the specific regions affected by Ab deposition. Taken
together with the observation that BACE1-deficient mice displayCdiminished amyloid pathology (Vassar et al., 2009), current
evidence strongly suggests that BACE1 elevation leads to
enhanced Ab production and deposition in AD. Given the central
role of Ab in AD pathogenesis and the fact that BACE1 is the
rate-limiting enzyme in APP processing and Ab generation,
BACE1 remains one of the most important therapeutic targets
for treating AD.
BACE1 expression is tightly regulated at multiple levels
between transcription and posttranslation (Rossner et al.,
2006). A number of transcription factors (TFs) have been identi-
fied that positively or negatively regulate BACE1 gene expres-
sion in both basal (Sp1, YY1, and HNF3b) (Ge et al., 2004; Sun
et al., 2005) and cell stress conditions (e.g., HIF-1a during hypox-
ia and NF-kB and PPARgwith inflammation) (Guglielmotto et al.,
2012). We recently reported differential regulation of BACE1 by
oxidative and nitrosative signals (Kwak et al., 2011), both of
which are common denominators in age-related diseases.
While the molecular mechanism underlying ischemia/hypoxia
or reactive oxygen species (ROS)-induced BACE1 activation and
APP processing has been extensively studied, relatively little is
known about BACE1 regulation by metabolic stress. The vast
majority of AD cases are late onset and sporadic (SAD) in origin,
with age being the most profound risk factor. Multiple environ-
mental factors, such as diet and lifestyle, along with genetic
factors are all significant contributors. Epidemiological, clinical,
and experimental evidence strongly link metabolic defects with
functional alterations associated with aging of the brain and
with AD pathogenesis. Thus, classic cardio-metabolic risk fac-
tors such as hypertension, cerebral hypoperfusion, diabetes
mellitus, and hypercholesterolemia have been shown to increase
the risk of SAD (Bhat 2010; Craft 2009; de la Torre 2009; Martins
et al., 2006).
In this study, we sought to investigate the potential role of
the sirtuin 1 (SIRT1), peroxisome proliferator-activated receptor
gamma (PPARg), and its coactivator (PGC-1) pathway in regu-
lating BACE1 expression. Using in vitro and in vivo experimental
systems mimicking metabolic stress (e.g., glucose depletion,
hyperglycemia, high-fat/high-cholesterol (HFC) diet, and fast-
ing), our work demonstrates the potent suppressive effects of
these key regulators on BACE1 transcription in response to
cellular metabolic status.ell Metabolism 17, 685–694, May 7, 2013 ª2013 Elsevier Inc. 685
Figure 1. HFC Feeding or eNOS Deficiency
Increases BACE1 Expression
(A) Western blot analysis of BACE1 protein
expression from the forebrain extracts of mice
fed HFC and control chow diets (n = 5/group;
9 months of age).
(B) Quantification of (A) by densitometry.
(C) Relative mRNA levels of BACE1 and PGC-1a
determined by qRT-PCR from the same forebrain
samples as in (A).
(D) Relative forebrain BACE mRNA levels of mice
with partial and complete eNOS deficiency (n = 5/
group). Western blot of eNOS protein expression
is shown on the top panel. *p < 0.05.
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SIRT1-PPARg-PGC-1 Represses BACE1 TranscriptionRESULTS
Elevated BACE1 Transcription by Feeding a HFC Diet or
eNOS Deficiency
Disrupted cholesterol homeostasis causes excessive Ab
generation (Puglielli et al., 2003). Previously, we observed that
young C57BL/6 mice consuming a HFC diet containing 21%
milk fat and 1.25% cholesterol for 8 weeks demonstrated
learning/memory deficits and neuroinflammation (Thirumanga-
lakudi et al., 2008). Since high cholesterol is the biggest risk
factor for SAD in middle-aged individuals, we repeated the
8 week HFC feeding regimen on middle-aged mice. BACE1
gene and protein expression levels were found to be in-
creased over 2-fold in the mouse forebrains after HFC feed-
ing (Figures 1A and 1B). Furthermore, we found that both
PGC-1a and PGC-1b messenger RNA (mRNA) levels were
significantly reduced following the HFC diet (Figure 1C).
BACE1 reduction appeared to be at the transcription level,
since we did not detect significant changes in the protein level
of GGA3, a key regulator of BACE1 trafficking and lysosomal
degradation (Tesco et al., 2007), or p-eIF2a (O’Connor et al.,
2008) (Figure S1).
Recently, we demonstrated that BACE1 is highly susceptible
to nitric oxide (NO)-mediated regulation. NO generated by the
endothelial NO synthase (eNOS) suppresses BACE1 transcrip-
tion via cGMP-PKG signaling (Kwak et al., 2011). Consistent
with this, BACE1 protein expression in the brains of eNOS-
deficient mice was found to be elevated (Austin et al., 2010).
We observed that the frontal brains of 4-month-old eNOS/
mice displayed significantly increased levels of BACE1 mRNAs
(Figure 1D) while heterozygous mice did not show significant
alteration.
Fasting Reduces BACE1 Expression in Mice
Calorie restriction can activate the AMP-activated protein kinase
(AMPK)-SIRT1-PGC-1 pathway (Qin et al., 2006). We therefore
examined the effect of fasting on BACE1 levels in mouse brains
and found that BACE1 expression was significantly reduced at
the 24 hr time point (Figures 2A and 2B), accompanied by
marked activation of AMPK and increased PGC-1a/PGC-1b
(Figures 2C and 2D). This inverse correlation between BACE1
and PGC-1 was also detected at mRNA levels (Figure 2E). Fast-686 Cell Metabolism 17, 685–694, May 7, 2013 ª2013 Elsevier Inc.ing for 24 hr resulted in >85 mg/dl blood glucose levels, which
are still within the normal range (Figure S2).
PGC-1 Regulates BACE1 In Vitro and In Vivo
Since AMPK and PGC-1 can both be activated by cGMP-PKG
signal transduction (Nisoli et al., 2003), we investigated whether
these key metabolic regulators have a direct role in suppressing
BACE1. In HEK293 cells, we found that overexpression of PGC-
1a suppressed basal transcription of endogenous BACE1
mRNA, resulting in a 2-fold reduction of mRNA and protein levels
(Figures 3A and 3B). On the other hand, downregulation of either
PGC-1a (52%) or PGC-1b (38%) gene transcription in rat primary
cortical neurons via specific small interfering RNA (siRNA)
delivered from adenoviral transduction resulted in >2-fold upre-
gulation of BACE1 protein expression (Figures 3C and 3D). A
direct role for PGC-1 in suppressing BACE1 expression was
also further confirmed by in vivo approaches. Overexpression
of PGC-1a (>7-fold) via AAV2-mediated gene transfer severely
diminished BACE1 protein expression in the hippocampi of
Tg2576 (a familial AD [FAD] model overexpressing an APPSwedish
mutant), while downregulation of PGC-1a (1.9-fold) augmented
BACE1 expression by 2.6-fold in the hippocampi of wild-type
(WT) C57BL/6 mice (Figures 3E and 3F). The effects were
confirmed to be on modulation of BACE1 transcription, as evi-
denced by the altered mRNA levels (Figure 3G). We found com-
parable effects of PGC-1a and PGC-1b in suppressing BACE1
upon transfection, indicating that they are interchangeable.
PGC-1’s Effect on BACE1 Requires Deacetylation by
SIRT1
As with elevating PGC-1 levels, overexpression of SIRT1 sup-
pressed BACE1 transcription, while deacetylase-inactive (DN)
H355A SIRT1 had the opposite effect in HEK293 cells (Fig-
ures 4A and 4B). Treatment with the SIRT1 activating agent,
resveratrol, repressed BACE1 transcription in a dose-dependent
manner (Figure 4C); concentrations greater than 50 mM caused
cytotoxicity in primary cultured neurons. On the contrary,
the SIRT inhibitor, sirtinol, significantly augmented BACE1 levels
at 10 mM (Figures 4D and 4E). BACE1 expression was up-
regulated 1.8-fold (Figure 4D) by 5 mM nicotinamide. Notably,
coexpression of PGC-1 and the DN-SIRT1 plasmid constructs
in HEK293 cells completely abolished the suppressive effect
Figure 2. Fasting Reduces BACE1 Expres-
sion in Mouse Brains
(A) Fasting reduces BACE1 expression in mouse
forebrains at 24 hr time point as determined by
western blot (n = 2/time point).
(B) Quantification of (A) based on densitometry.
(C) Western blot analysis of BACE1 and PGC-1a/
PGC-1b protein in mouse forebrain after 24 hr of
fasting.
(D) Quantification of westerns in (C).
(E) mRNA abundance of BACE1 and PGC-1a/
PGC-1b. Data are represented as means ± SD; n =
3–5 mice/group; *p < 0.05.
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SIRT1-PPARg-PGC-1 Represses BACE1 Transcriptionmediated by PGC-1 on BACE1 protein levels (Figure 4E). DN-
SIRT1 coexpression was found to increase PGC-1 acetylation.
Under an extreme no glucose (NG) condition, which is known
to cause neuronal toxicity, BACE1 transcription and expression
were found to be elevated, accompanied by decreased expres-
sion levels of SIRT1 and PGC-1 as well as PGC-1 activity
(increased acetylation); overexpression of PGC-1 completely
reversed the detrimental effect of NG on BACE1 (Figure S4).
Recently, SIRT1 was also reported to activate PPARg via de-
acetylation on K268 and K293 in ‘‘browning’’ adipocytes (Qiang
et al., 2012). Since PGC-1 was classically defined as the coacti-
vator to PPARg, we also investigated the role of PPARg and its
deacetylation in BACE1 suppression. In cultured neurons, treat-
ment with rosiglitazone (PPARg ligand) andGW9662 (irreversible
antagonist) led to opposing effects on BACE1 expression in a
dose-dependent manner (Figure 5A). Interestingly, PGC-1’s
suppressive effect was largely abolished by GW9662, but
unaffected by rosiglitazone, indicating a ligand-independent
mechanism (Figure 5B). In 24 hr fasted mouse brains, the acety-
lated forms of both PGC-1 and PPARgwere reduced (Figure 5C).
Notably, overexpression of nonacetylated PPARg (K268T and/or
K293T), which represents the active form, repressed BACE1
transcription to a similar degree to that of PGC-1 or SIRT1 in a
ligand-independent manner (Figure 5D). Surprisingly, overex-
pression of WT PPARg did not exert a significant effect on
BACE1, indicating that the molecule is not limiting in neurons.
In addition, coexpression of SIRT1 with PPARg resulted in an
effect similar to that of PGC-1 ormutant PPARg. However, coex-
pression of PGC-1 with WT SIRT1 did not exert a further additive
effect. Similar results were observed not only on the endogenous
BACE1 mRNAs, but also on the transfected rBACE1-luciferase
(Luc) reporter assay (Figure S5). Taken together, these data
strongly indicate that SIRT1 is the upstream regulator of PPARg
and PGC-1.
SIRT1, PPARg, and PGC-1 Directly Interact with the
Promoter
To investigate the mechanism by which PPARg-PGC-1a re-
presses BACE1 transcription, we first investigated if these
molecules play a suppressive role on BACE1 via the PPARg-
responsive element (PPRE) identified previously under inflam-
matory conditions (Sastre et al., 2006). Analysis of the BACE1Cpromoter identified four potential PPAR-RXR-responsive ele-
ments (Figure S6, sites 1–4). We generated a series of deletion
mutants for the BACE1 promoter and compared their promoter
activities. All of the deletions resulted in significantly increased
basal promoter activity with an exception on the F9 construct
(Figures 6A and 6B). The findings that constructs F7 and F8
resulted in a 2-fold increase in BACE1 promoter activity sug-
gested that the 1,541/1,209 region contains elements that
negatively regulate BACE1 (e.g., sites 1 and 2). The F9 construct,
which lacks the HNF-3 binding site, displayed normal BACE1
promoter activity, as compared to WT F1, suggesting that
HNF-3 is a strong positive TF. Further deletion (F2) up to the
753 region regained increased BACE1 promoter activity, indi-
cating the presence of additional negative regulatory elements.
Notably, the repressive effect of PGC-1 overexpression was
lost from all of the deletion promoters, indicating that PGC-1
suppresses in part through the N-terminal region.
Between sites 1 and 2, only the first site displays a typical
PPRE motif. Further disruption of the 1,357/1,333 PPRE by
site-directed mutagenesis led to a 36% increase in luciferase
activity. In addition, mutation of the YY1 site-mutated promoter
resulted in a 48% reduce in reporter activity (Figures 6C and
6D), consistent with the report that YY1 is a key positive TF
for BACE1 (Nowak et al., 2006). Interestingly, when either the
PPRE or YY1 site was mutated, PGC-1 overexpression lost its
suppressive effect on BACE1 promoter transcription. Downre-
gulation of PGC-1 had no effect on the BACE1-luc with a
mutated PPRE. These results strongly indicated that PPRE
was the major site at which PGC-1 exerts its regulatory effect
on the BACE1 promoter. To seek more direct in vivo evidence
of PGC-1’s effect on this PPRE, we conducted a chromatin
immunoprecipitation (ChIP) assay on the 24 hr fasted mouse
brains to show that the SIRT1, PGC-1, and PPARg proteins are
associated with the first PPRE site (Figures 7A and S7A). Indeed,
similarly enhanced protein-protein interactions between PGC-1
and SIRT1 and with PPARgwere detected by coimmunoprecipi-
tation in the fasted brains (Figure 7D).
By in vivo ChIP, we further detected increased binding of
SIRT1, PPARg, and PGC-1 on the other three elements (sites
2–4) in the fasted brains (Figures 7B and S7B), with the most
prominent enhancement observed on sites 1 and 3. Interestingly,
we also detected markedly enhanced binding of a nuclearell Metabolism 17, 685–694, May 7, 2013 ª2013 Elsevier Inc. 687
Figure 3. Suppression of BACE1 Expres-
sion In Vitro and In Vivo by PGC-1
(A) Effects of overexpressed myc-tagged-PGC-1a
on BACE1 protein expression. Protein levels were
measured in HEK293 cells 48 hr after transient
transfection (2 mg) by western blot analysis. The
BACE1 monoclonal antibody (3D5) used was
raised in BACE1 null mice. PGC-1a protein was
detected by an anti-Myc antibody. Protein levels in
the left panel were quantified by densitometry
analysis (right panel).
(B) Effect of overexpressed PGC-1a on the
endogenous levels of BACE1 mRNA as deter-
mined by qRT-PCR 48 hr after transfection.
(C) Downregulation of PGC-1 (PGC-1a or PGC-1b)
by shRNA upregulates BACE1 expression in
primary neurons. Rat primary neurons (DIV10)
were infected with PGC-1 shRNA adenovirus for
48 hr. BACE1 protein expression was detected by
western blot and quantified based on data from
four experiments. Infection efficiency was moni-
tored by the EGFP signals under microscope and
by qRT-PCR.
(D) PGC-1a and PGC-1b mRNA levels following
knockdown are shown.
(E) Effects of PGC-1a overexpression and downregulation on BACE1 expression in vivo. AAV2-PGC-1a or AAV2-EGFP (vehicle, 109 virus particles in 1 ml) was
injected into the CA1 region of Tg2576mouse hippocampi (n = 5/group, 5-month-oldmice), and BACE1 protein was determined by western blot analysis 4 weeks
later.
(F) AAV2-PGC-1a-shRNA and AAV2-EGFP (1010 viruses particles in 1 ml) were injected into the CA1 of C57BL/6mice (n = 5/group; 4-month-old mice), and BACE1
level was determined 4 weeks later.
(G) ThemRNA levels of BACE1 and PGC-1a in hippocampi as determined from the same animals for the studies in (E) and (F). No cytotoxicity was detected at the
time of the in vitro assays. Data are represented as means ± SD from five to seven independent experiments; *p < 0.05, **p < 0.01.
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SIRT1-PPARg-PGC-1 Represses BACE1 Transcriptionreceptor corepressor (NcoR) on sites 1 and 3. Based on our
preliminary results, we did not see binding of the other major
ligand-independent corepressor SMRT/NCoR2 to the BACE1
promoter, suggesting a corepressor specificity of NCoR in terms
of negative regulation of BACE1. Further ChIP analysis was con-
ducted on the three positive sites (HNF-3, Sp1, and YY1). As pre-
dicted, none of the binding of these positive transcription factors
was significantly altered upon fasting (Figures 7C and S7C),
while enhanced PGC-1 was found at the HNF-3 and Sp1 sites.
SIRT1 binding was either undetected or unaltered.
DISCUSSION
This work was designed to explore mechanisms through
which the altered expression of the components of the SIRT1-
PPARg-PGC-1 pathway may regulate BACE1 expression. Here-
in, we present in vitro and in vivo evidence for the transcriptional
regulation of BACE1 by this dominant metabolic signaling
pathway under basic and metabolic stress conditions. Our
findings provide a fresh molecular basis for metabolic factors
regulating a crucial and rate-limiting enzyme in AD pathogenesis.
Given the increasing recognition of several major cardio-
metabolic risk factors (e.g., central nervous system [CNS] insulin
resistance, high cholesterol, ApoE genotype, insufficient eNOS,
etc.) in accelerating AD development and progression, the
unique transcriptional regulation of BACE1 identified here may
represent a unifying and central mechanism for aberrant amyloi-
dogenesis induced by increased metabolic stress.
PGC-1a was classically defined as a transcription coactivator
that interacts with a broad range of TFs that participate in many688 Cell Metabolism 17, 685–694, May 7, 2013 ª2013 Elsevier Inc.biological processes, including adaptive thermogenesis, mito-
chondrial biogenesis, glucose/fatty acid metabolism, muscle
fiber-type switching, and heart development (Lin et al., 2005).
Dysregulated PGC-1a has been implicated in pathogenic condi-
tions such as obesity, type 2 diabetes, and cardiomyopathy. The
evidence for PGC-1a transcriptional interference in neurodegen-
eration was initially supported by the discovery of Huntington-
like striatal degeneration in PGC-1-deficient mice (Cui et al.,
2006; Lin et al., 2004; Weydt et al., 2006). Its role was recently
extended to Parkinson’s disease (Clark et al., 2011; Zheng
et al., 2010) and to non-neuronal lineages (Tsunemi and La
Spada 2012; Xiang et al., 2011). However, little is known of its
role in AD other than reduced expression in the brains of AD
patients and Tg2576 mice with insulin resistance induced by a
HFD (Ho et al., 2004; Katsouri et al., 2011; Qin et al., 2009).
Both PGC-1 isoforms (PGC-1a and PGC-1b) are abundantly
expressed and widely distributed in the brain and may be
interchangeable for certain functions, including neuronal mito-
chondrial biogenesis (Wareski et al., 2009), as well as in
BACE1 transcriptional regulation as reported here. Recent
studies in CaMKII-specific PGC-1a conditional knockout (KO)
mice (Ma et al., 2010) suggested a crucial role for PGC-1 in
neuronal function with forebrain neurons as an important and
integral part of the neural circuitry in governing energy balance.
Caloric restriction has been shown to induce multiple changes
in glucose metabolism and extend lifespan in a broad spectrum
of species, possibly attributable to the activated AMPK-SIRT1-
PGC-1 signaling pathway. In the liver, SIRT1, the NAD-depen-
dent protein deacetylase, controls the gluconeogenic/glycolytic
pathways in response to fasting through interaction with and
Figure 4. PGC-1 Suppression of BACE1
Requires SIRT1 Deacetylase Activity
(A) Effects of overexpressed WT and a dominant-
negative mutant SIRT1 (SIRT.H355A) on BACE1
protein expression HEK293 cells. Protein levels
were detected in HEK293 cells 48 hr after transient
transfection.
(B) The endogenous BACE1 mRNA levels upon
SIRT1 transfection were determined by qRT-PCR
and quantified based on three independent ex-
periments.
(C–E) Effects of resveratrol (C), sirtinol (D), and
nicotinamide (E) at various concentrations on
BACE1 mRNA or protein levels in primary neurons
6 hr after treatment. Data are represented as
means ± SD from three independent experiments;
*p < 0.05; **p < 0.01.
(F) Effect of SIRT1-mediated deacetylation of
PGC-1b on BACE1 suppression. Myc-tagged
PGC-1b was cotransfected with dominant-nega-
tive mutant SIRT1 in HEK293 cells, and protein
levels were determined 48 hr later. PGC-1 acety-
lation was detected after immunoprecipitation
with an anti-Myc antibody and then probed with
anti-acetylated lysine antibody (Cell Signaling
Technology).
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SIRT1-PPARg-PGC-1 Represses BACE1 Transcriptiondeacetylation of PGC-1a at specific lysine residues in an
NAD(+)-dependent manner (Rodgers et al., 2008). These find-
ings regarding the basic pathways of energy homeostasis in
the liver appear to be replicated in the brain during the regulation
of BACE1. Under nonfasting conditions, PGC-1a is expressed at
very low levels in the brain but PGC-1a is induced by fasting. The
expression and activity of PGC-1a in the brain are modulated by
transcriptional activation as well as by SIRT1-mediated deacety-
lation, which increases PGC-1 activity. Like PGC-1, SIRT1 has
emerged as a major regulator of mammalian transcription in
response to cellular metabolic status and stress. It has been
shown to positively regulate a-secretase promoter transcription,
leading to reduced amyloid deposition (Donmez et al., 2010). As
with exercise (Lazarov et al., 2005), calorie restriction mitigated
excessive amyloidogenesis in Tg2576 brains via activation of
a-secretase through SIRT1-mediated transcriptional activation
of FoxO3a (Qin et al., 2008).
Is Transcriptional Dysregulation of BACE1 a Crucial
Mechanism in SAD?
Despite overwhelming evidence of robust transcriptional activa-
tion of BACE1 in response to various stress conditions in
numerous experimental models, including both cellular and
rodent AD, the majority of earlier studies failed to detect signifi-
cant elevation of the mRNA level of BACE in AD patient brains
(Gatta et al., 2002; Preece et al., 2003; Yasojima et al., 2001),
with one exception (Li et al., 2004). In addition, a recent large-
scale, candidate-gene SNP-expression screen showed compa-
rable BACE1 expression in the cortex of late-onset AD/LOAD
cases and age-matched controls (10.815 ± 0.038 in 187 cases
of control versus 10.763 ± 0.039 in 176 cases of LOAD) (Webster
et al., 2009). Since neuron density is much lower in AD cases, aCstable expression value actually indicates higher expression per
neuron. The discrepancy between experimental models (Tgmice
and cultured neurons) versus primary AD brain specimens may
also arise in part from the sporadic nature of the majority of AD
cases, with BACE1 being tightly regulated by multiple mecha-
nisms that are not necessarily mutually exclusive. It should be
noted that one recent report found significantly increased
BACE1 mRNAs in freshly isolated peripheral blood mononuclear
cells (PBMCs) from a large cohort of ADpatients, as compared to
normal controls (Marques et al., 2012).
Although our data clearly indicate transcriptional regulation
of BACE1 as the dominant event in response to metabolic
stress, we cannot rule out the possibility of translational regula-
tion. In a previous report, the treatment of mice with an acute
energy inhibitor only increased BACE1 protein levels, but not
mRNA levels, primarily due to elevated eIF2a phosphorylation
via a translational control mechanism. Elevated p-eIF2a and
BACE1 levels were also observed in 5XFAD transgenic mice
and in human AD brains (O’Connor et al., 2008). It should be
pointed out that the translational upregulation of BACE1 upon
energy depletion using toxins to mitochondrial respiratory
chains may be mechanistically different from fasting or calorie
restriction used in our studies in terms of elicited changes in
signaling pathways though PGC-1. We did not detect a signifi-
cant increase in p-eIF2a in the mouse brains after HFC feeding.
Nevertheless, the two major transcriptional and translational
mechanisms need not be mutually exclusive, and it is unclear
which mechanism may play a more important role in sporadic
AD pathogenesis. Moreover, metabolic stress may elicit addi-
tional regulatory mechanisms posttranscriptionally (microRNA)
(Wang et al., 2008) and posttranslationally (ubiquitination, S-ni-
trosylation, and oxidation) (Kwak et al., 2011). Together withell Metabolism 17, 685–694, May 7, 2013 ª2013 Elsevier Inc. 689
Figure 5. PGC-1’s Suppressive Effect
Requires Active PPARg and Involves
SIRT1-Mediated Deacetylation
(A) Opposing effects of rosiglitazone and GW9662
on BACE1 expression levels. Western blot
analysis was conducted at 6 hr after treatment in
neurons.
(B) PGC-1a effect is dependent on active PPARg
but not on its ligand. Rosiglitazone or GW9662
compounds were added to the HEK293 cells
24 hr after transfection with PGC-1a plasmid, and
BACE1 gene transcription was determined 6 hr
later by qRT-PCR. Data are represented as
means ± SD from three independent experiments;
*p < 0.05.
(C) Acetylation status of PPARg, PGC-1a, and
PGC-1b was determined by western blotting.
(D) PPARg represses BACE1 in its active, non-
acetylated form. Various plasmids were trans-
fected, alone or in combination, into HEK293
cells, and BACE1 qRT-PCR was conducted 24 hr
later. For (C) and (D), data are represented as
means ± SD from three independent experiments;
*p < 0.05, **p < 0.01. ‘‘n.s.’’ indicates statistically
nonsignificant.
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SIRT1-PPARg-PGC-1 Represses BACE1 Transcriptionrecently disclosed epigenetic DNA methylation (Marques et al.,
2012), BACE1 has proven to be tightly regulated by multiple
mechanisms. Lastly, BACE1 protein degradation is emerging
as a potentially important regulatory mechanism, and PGC-1a
was reported to facilitate BACE1 protein degradation via the
ubiquitin proteasome system (UPS) (Gong et al., 2010), which
may also reflect one of the multiple effects of this key regulatory
molecule. Interestingly, we also did not detect changes in the
GGA3 protein upon metabolic stress, a mechanism discovered
in response to cerebral ischemia and brain injury (Walker et al.,
2012).
Perhaps due to technical limitations, several earlier studies
did not see evidence of BACE1 transcriptional regulation
under HFD-induced insulin resistance or by resveratrol (Ho
et al., 2004; Vingtdeux et al., 2010). Of particular interest, the
anti-amyloidogenic effect of resveratrol was attributed to
the AMPK-mediated signal modulation of mTOR-autophagy,
thereby facilitating BACE1 protein degradation and clearance
(Dasgupta and Milbrandt 2007). Our study, based on the
different experimental designs (NG, fasting, and HFC), has
unequivocally demonstrated BACE1 transcriptional alteration
as a key response to metabolic stress. Among the major
components of the identified transcription circuitry and net-
work are the PGC-1a-assisted PPARg transcription complexes,
which act via direct interaction with the PPRE located in
the BACE1 promoter. We have also identified a molecular
mechanism whereby SIRT1 functions in glucose homeostasis
as a modulator of both PPARg and PGC-1a. Enhanced func-
tional interaction between SIRT1-PGC-1a, along with PPARg-
PGC-1a, has been found in fasting brains as detected by
immunoprecipitation of molecular complexes (Figure 7D). These
functional interacting partners have been identified as required
to mediate nutrient control of glucose homeostasis in peripheral
tissues (Rodgers et al., 2008). Hence, our findings demonstrate
that the basic mechanisms of energy homeostasis can regulate
BACE1.690 Cell Metabolism 17, 685–694, May 7, 2013 ª2013 Elsevier Inc.Unique Molecular Mechanism Repressing BACE1
Transcription
This is a unique report of transcriptional inhibition by PPARg-
PGC-1a. The standard view of PPARg-PGC-1-mediated tran-
scription involves transcriptional upregulation of genes in a
ligand-dependent manner. However, there are several reports
suggesting that increases in PGC-1a levels can negatively
impact the expression of certain genes via indirect and poorly
understood mechanisms (Estall et al., 2009; Jeong et al., 2009;
Zhang et al., 2004). One unresolved issue is how PPARg-
PGC-1 is able to repress transcription. There are several pos-
sible mechanisms: (1) The peroxisome proliferator responsive
elements (PPREs) in the BACE1 promoter serve as negative
PPREs and convert PPARg into a transcriptional repressor. (2)
PPARg-PGC-1 act as scaffolding proteins rather than TF and
coactivator, thereby allowing reverse recruitment of corepres-
sors. Based on literature, PPARg can either functionally antago-
nize certain positive TFs to repress transcription or recruit
corepressors (Cohen 2006, Perissi et al., 2010). (3) SIRT1 re-
presses PPARg by docking with corepressors (NCoR and
SMRT) as in adipocytes (Picard et al., 2004). (4) There are other
critical proteins bound on the BACE1 promoter, such as HNF-3,
YY1, or SP1, that convert PGC-1a into a transcriptional
repressor. Our preliminary work has explored these possibilities
and ruled out the PPRE. When two copies of each of the PPAR-
RXR elements (sites 1–4) in the BACE1 promoter were ligated 50
to the luciferase gene, none of these elements were able to
repress expression of the luciferase reporter (F.-F.L., unpub-
lished data). With respect to the involvement of corepressors,
we found that NCoR was recruited into the promoter complexes
with PPARg, PGC-1, and SIRT1, and this recruitment was inde-
pendent of rosiglitazone addition. Upon fasting, the association
of both PGC-1 andNCoRwas enhanced on the BACE1 promoter
(Figure 7B). This finding supports the second and third possibil-
ities, which are not mutually exclusive. The strongest finding of
this work is on the coexistence of both corepressor NCoR and
Figure 6. PGC-1’s Suppressive Effect Is
Largely Dependent on the First PPRE Site
(A) Schematic diagram of BACE1 promoter (rat,
1.54 kb) in pGL3-basic luciferase construct. Con-
structs F2–F9 represent four BACE1 promoter
deletions.
(B) Effects of transfecting PGC-1a on BACE1
promoter activity. Relative BACE1 promoter
activity from the various deletion constructs is
presented as compared to full-length BACE1-luc
(F1). Data are represented as means ± SD from
five independent experiments; *p < 0.05.
(C) Effects of PPRE and YY1 mutants on BACE1
promoter activity. PGC-1awas cotransfected with
rat BACE1 promoter (WT) or its mutants that are at
PPRE or YY1 sites into HEK293 cells. Luciferase
assay was performed 24 hr after transfection.
Relative BACE1 promoter activity from the
mutants and the effects of PGC-1a are presented
as compared to pcDNA3.1 vector-cotransfected
BACE1-luc (WT) activity.
(D) Effect of the PPRE-mutated promoter on
PGC-1 in BACE1 suppression. AAV-PGC-1a
shRNA was cotransfected with rat BACE1 pro-
moter and its PPRE mutant into HEK293 cells for
24 hr. Data are presented as means ± SD from at
least three independent experiments; *p < 0.05.
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vated by deacetylation as demonstrated by the K mutants,
PPARg negatively regulated BACE1 transcription. Since we
observed specific effects from overexpressing the mutant
PPARg at K268T and K293T in suppressing BACE1 transcrip-
tion, and SIRT1 is known to deacetylate from these two residues,
SIRT1 is likely responsible for the PPARg activation in our case.
However, it is not clear whether such deacetylation is ligand
dependent as reported in adipocytes (Qiang et al., 2012); our
data argue against a ligand-independent mechanism, likely
reflecting a cell-type-specific mechanism in neurons. It is also
unclear whether PPARg activation by SIRT1 is required to recruit
the corepressor NCoR. Although we detected in vivo binding of
SIRT1, PPARg, and PGC-1 on the multiple nuclear receptor
response elements, with most prominent binding found on sites
1 and 3, PGC-1 was also found at the HNF-3 and Sp1 sites.
There has been one previous report that resveratrol inhibited
expression of the angiotensin II type 1 receptor gene through
Sp1, raising the possibility that SIRT1 may inhibit BACE1 in
part through Sp1 (Miyazaki et al., 2008). Based on the data we
collected, we speculate a loop topology as illustrated in the
Graphical Abstract in a simplified format: binding of the common
factors to sites 1 and 3 and to HNF-3 may present the recruited
corepressor to the positive TF. It is not yet known whether the
corepressor NCoR is also recruited to these positive TFs and if
its recruitment requires, or is assisted by, PGC-1.
Although the complex regulatory mechanism, in terms of the
interplay between these molecules, warrants further investiga-
tion, our work strongly suggests that targeting BACE1 at the
transcriptional level may be a viable approach for SAD, as
demonstrated in a FAD mouse model using lenti-siRNA, leading
to a complete reversal of excessive amyloidogenesis and neuro-
degeneration (Singer et al., 2005). Although our results based onCadministration of the AAV2-PGC-1a viruses are preliminary due
to a small number of Tg2576 mice (Figure 3), they show promise
of the therapeutic value of overexpressing or activating PGC-1 in
blunting amyloidogenesis in a FAD model. Furthermore, virus-
mediated gene delivery of SIRT1 and PGC-1 have demonstrated
proof of concepts in halting neurodegeneration inHuntington dis-
ease (HD) and AD mouse models (Jeong et al., 2012; Kim et al.,
2007; Tsunemi and La Spada, 2012; Tsunemi et al., 2012). Our
major findings on themolecular pathway under variousmetabolic
stress conditions further suggest a promise of generalizing a
PGC-1-based approach in SAD. Therefore, further characteriza-
tion of the transcription network involving PGC-1a, SIRT1, and
the BACE1 promoter will further validate the metabolic factors
regulating this important gene in Alzheimer’s etiology. More
importantly, the study outcomes may be instrumental in future
therapeutic design regarding targeting SAD.
EXPERIMENTAL PROCEDURES
Cell Culture, Drug Treatments, Plasmid Transfection, and Virus
Infection
Rat primary cortical neurons (PRCN) were prepared as described (Chen et al.,
2009). Glucose deprivation was performed with Dulbecco’s modified Eagle’s
medium (DMEM; GIBCO) without glucose or Neurobasal medium without
glucose overnight. Treatments with 10–100 mM resveratrol or 5 mM nicotin-
amide (Sigma-Aldrich) were performed overnight at 37C. Transient transfec-
tions were performed using Lipofectamine 2000 (Invitrogen) with plasmids:
pcDNA-PGC-1a and pcDNA-PGC-1b (Addgene); pcDNA4 TO-Myc.His-
PGC-1a or b; pcDNA-SIRT1.WT and its mutant SIRT1.H355A. pGL3-basic
luciferase reporter constructs and the site-directed mutagenesis was per-
formed as described in our previous work (Chen et al., 2009; Kwak et al., 2011).
In Vivo Experiments on Mice
All animal care protocols and procedures were performed in accordance with
the Animal Scientific Procedures Act and with the approval of the Universityell Metabolism 17, 685–694, May 7, 2013 ª2013 Elsevier Inc. 691
Figure 7. Enhanced In Vivo Binding of
SIRT1, PPARg, PGC-1a, and Corepressor
NCoR to Multiple Sites of the BACE1 Pro-
moter Region
(A) In vivo ChIP assay detected increased binding
of endogenous PGC-1a, SIRT1, and PPARg in
the protein complex to the first PPRE site in
mouse brains upon 24 hr fasting as compared
to nonfasted samples. Frontal cortical tissues
were pooled from four mice per group. **p < 0.01,
***p = 0.005.
(B and C) Representative results from the in vivo
ChIP assay showing binding on sites 1–4 (B) and
on the Sp1, YY1, and HNF-3b sites (C) using the
same 24 hr fasted mouse brains.
(D) Enhanced SIRT1-PGC-1 and PPARg-PGC-1a
interactions upon fasting. Fasted and control
mouse forebrain lysates were immunoprecipitated
by anti-PGC-1a antibody followed by western blot
probing with either SIRT1 or PPARg antibody.
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custom diet containing 21% fat and 1.25% cholesterol (D12079B, Teklad, Har-
lan Laboratories) was given to C57BL/6 mice from a 5-month-old group (n = 5/
group) for 2 months and compared to a control chow diet. AAV2/AAV5 PGC-
1a-small hairpin RNA (shRNA; 3.873 1013 vg/ml, 50-GGTGGATTGAAGTGGTG
TAGA-30) and AAV2/5-enhanced green fluorescent protein (EGFP; 2.563 1013
vg/ml) were generated by the Virus Core Facility at IowaUniversity, and AAV2/1
viruses overexpressing PGC-1a were generated in-house (2 3 1012 vg/ml). All
AAV2 viruses were injected into the CA1 region of mouse hippocampus in 1 ml
of volume, and mice were euthanized 21 days later for analysis.
Immunoprecipitation and Immunoblot
The procedures were performed as described (Chen et al., 2009; Kwak et al.,
2011) using the following antibodies: mouse anti-BACE1 (3D5); mouse anti-
Myc and mouse anti-b-actin (Sigma-Aldrich); Rabbit anti-SIRT1 (Millipore);
mouse anti-PPARg (81B8); rabbit polyclonal antibodies against p-AMPKa,
AMPKa, acetylated lysine, p-eIF2a, and eIF2a, GGA3 (Cell Signaling Technol-
ogy); and mouse anti-PGC-1a (H-300; Santa Cruz).
Quantitative RT-PCR on BACE1 and PGC-1 Messages
The procedures were performed as described using the same primers for rat
and human bace1 (Chen et al., 2009; Kwak et al., 2011). Rat pgc-1a primers
(forward 50-AAAGGGCCAAGCAGAGAGA-30 and reverse 50-GTAAATCACA
CGGCGCTCTT-30), rat pgc-1b primers (forward 50- TTGACAGTGGAGCTTT
GTGG-30 and reverse 50-GGGCTTATATGGAGGTGTGG-30 ), human pgc-1a
primers (forward 50- TTATTGGGAAATGCCTCCTG-30 and reverse 50- GGGT
CATTTGGTGACTCTGG-30), mouse pgc-1a primers (forward 50- GAAAGGGC
CAAACAGAGAGA-30 and reverse 50- GTAAATCACACGGCGCTCTT-30), and
mouse pgc-1b primers (forward 50- CTCCAGTTCCGGCTCCTC-30 and reverse
50- CCCTCTGCTCTCACGTCTG-30) were used in the present studies. Primers
used for rat GAPDH, forward 50-ACATTGTTGCCATCAACGAC-30, reverse
50-CTTGCCGTGGGTAGCGTCAT-30; human GAPDH primers, forward 50-AA
TCCCATCACCATCTTCC-30 and reverse 50-GGACTCCACGACGTACTCA-30;
mouse GAPDH primers, forward 50- GGGTTCCTATAAATACGGACTGC-30
and reverse 50-CCATTTTGTCTACGGGACGA-30.
Promoter Deletion Constructs and Luciferase Assay
Deletion constructs and luciferase assayswere conducted as described (Chen
et al., 2009). PGC-1a or SIRT1 expression vectors or PGC-1 shRNA plasmids
were cotransfected into HEK293 cells; 24 hr later, cells were collected in pas-
sive lysis buffer and analyzed for luciferase activity. No-glucose treatment was
performed 5 hr after transfection.
ChIP assays
Chromatin immunoprecipitation (ChIP) assays were performed using the kit
from Upstate according to the manufacturer’s instructions. The transfected692 Cell Metabolism 17, 685–694, May 7, 2013 ª2013 Elsevier Inc.HEK293 cells were crosslinked with 1.0% formaldehyde and collected in lysis
buffer. The following primers were used in PCR assays: for site 1, forward
50-GAGTAATGTTGGTATGCCTC-30 and reverse 50- GGGATGAGAGTATGT
CAGTC-30; for site 2, forward 50-GCTCCTCCAGTCTCTACTCC-30 and reverse
50-GACTACATAGAGAAACTCTG-30. For detecting in vivo protein bindings,
mouse forebrain lysates (20 mg/immunoprecipitation) were used.
Statistics
All quantitative data are presented as means ± SD. Comparisons between
groups were analyzed with t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at http://dx.doi.org/10.1016/j.cmet.2013.03.016.
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